中国全科医学2024，Vol.27Issue(12)：1405-1412,8.DOI:10.12114/j.issn.1007-9572.2023.0849
《他汀类药物用于成年人心血管疾病的一级预防:美国预防临床服务指南工作组推荐声明》解读
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults:Interpretation of the U.S.Preventive Services Task Force Recommendation Statement
史威力 1李明艳 2段红艳3
作者信息
- 1. 450003 河南省郑州市,河南省人民医院 郑州大学人民医院全科医学科
- 2. 450003 河南省郑州市,河南省人民医院 郑州大学人民医院国际医疗中心
- 3. 450003 河南省郑州市,河南省人民医院 郑州大学人民医院全科医学科||450003 河南省郑州市,河南省人民医院 郑州大学人民医院国际医疗中心||450003 河南省郑州市,河南省人民医院 郑州大学人民医院老年医学科
- 折叠
摘要
Abstract
Cardiovascular disease(CVD)is the leading cause of death.It is well known that statins can reduce the risk of CVD and CVD-related death through lipid-lowering,anti-inflammatory,and plaque-stabilizing effects.In August 2022,the U.S.Preventive Services Task Force(USPSTF)conducted an updated recommendations statement on statins for primary prevention of CVD based on new evidence on the benefits and potential harms of statins in reducing CVD morbidity/mortality and all-cause mortality.The USPSTF recommends statins for the primary prevention of CVD for adults aged 40 to 75 years with 1 or more CVD risk factors and an estimated 10-year CVD risk of 10％or greater(B recommendation).The USPSTF recommends that clinicians selectively offer statins for the primary prevention of CVD in adults aged 40 to 75 years who have 1 or more of CVD risk factors and an estimated 10-year CVD risk of 7.5％to less than 10％(C recommendation).The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of using statins for primary prevention of CVD events and mortality in adults aged 76 years and above(I statement).This article interprets the latest recommendations in the context of China to provide reference for the use of statins for the primary prevention of CVD in China.关键词
心血管疾病/他汀类药物/一级预防/成年人/指南Key words
Cardiovascular diseases/Statins/Primary prevention/Adult/Guidebook分类
医药卫生引用本文复制引用
史威力,李明艳,段红艳..《他汀类药物用于成年人心血管疾病的一级预防:美国预防临床服务指南工作组推荐声明》解读[J].中国全科医学,2024,27(12):1405-1412,8.
